Immunotherapy: Targeting tumour heterogeneity

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, explains that anti-tumour immunity has the potential to be exploited clinically against the evolutionary process that drives cancer development.

Year of Production:
Running Time:
Color/Sound:

2015
02:05
Color/Sound

Comments are closed.